Monoclonal Anti-Glutamic Acid Decarboxylase 67 (GAD67), Clone K-87
produced in mouse, purified antibody

Catalog Number G5419

Product Description
Monoclonal Anti-Glutamic Acid Decarboxylase 67 (GAD67) (mouse IgG1 isotype) is derived from the K-87 hybridoma produced by the fusion of mouse myeloma cells and splenocytes from a mouse immunized with a synthetic peptide from mouse GAD67 (amino acids 87-106). This peptide does not share homology with GAD65. The antibody is expressed by hybridoma cell line grown in serum-free medium.

Monoclonal Anti-Glutamic Acid Decarboxylase 67 specifically recognizes GAD67. This monoclonal antibody can be used in various immunohistochemical techniques including immunohistochemistry and immunoblotting. Species reactivity includes mouse, rat, and human. There is no detectable cross-reactivity with GAD65 on immunoblots using mouse brain.

Glutamic Acid Decarboxylase (GAD) catalyzes the conversion of L-glutamate to γ-aminobutyric acid (GABA), the principal inhibitory neurotransmitter in the brain, and a putative paracrine signal molecule in pancreatic islets. GAD has a restricted tissue distribution. It is highly expressed in the cytoplasm of GABAergic neurons in the central nervous system (CNS) and pancreatic β-cells, but is also present in other non-neuronal tissues such as testis, ovudit and ovary. GAD is also transiently expressed in non-GABAergic cells of the embryonic and adult nervous system, suggesting its involvement in development and plasticity.

GAD exists as two isoforms, GAD65 and GAD67 (molecular masses of 65 and 67 kDa, respectively) that are encoded by two different genes.

GAD65 is an amphiphilic, membrane-anchored protein, (585 amino acid residues) and is encoded on human chromosome 10. GAD67 is a cytoplasmic protein (594 amino acid residues) and is encoded on chromosome 2. There is 64% amino acid identity between the two isoforms, with the highest diversity located at the N-terminus, which in GAD65 is required for targeting the enzyme to GABA-containing secretory vesicles. The two isoforms appear to have distinct intraneuronal distribution in the brain. GAD65 has been identified as an autoantigen in insulin-dependent diabetes mellitus (IDDM) and stiff-man syndrome (SMS). IDDM is an autoimmune disease that results from T cell mediated destruction of pancreatic insulin-secreting β-cells. Islet-reactive T cells and antibodies primarily to GAD65 (also named β-cell autoantigen) are detected in peripheral blood of 80% of recent-onset IDDM patients and in pre-diabetic high-risk subjects before onset of clinical symptoms. This suggests that GAD may be an important marker in the early stages of the disease. Also, autoantibodies to GAD65 and GAD67 are detected in animal models of IDDM, including the non-obese diabetes (NOD) mouse. In the NOD mouse, T cell reactivity is initially restricted to the C-terminal regions of GAD65, but later spreads to other parts of GAD65. Stiff-man syndrome (SMS), a rare disorder of the CNS, is characterized by progressive rigidity of the body musculature with painful spasms, due to impairment of the GABAergic neurotransmission.

High-titer autoantibodies directed against GAD65 and GABAergic neurons (nerve terminals) have been detected in the serum and cerebrospinal fluid (CSF) in 60% of patients with the syndrome. Strikingly, many of the SMS patients also developed late-onset IDDM.

Antibodies that react specifically with GAD 65 and GAD67 are useful for the study of differential tissue expression and intracellular localization of the isoforms in normal and disease conditions.

Reagent
Supplied in phosphate buffered saline containing 0.01% sodium azide.

Antibody concentration: ~1 mg/ml

Precautions and Disclaimer
For R&D use only. Not for drug, household, or other uses. Please consult the Safety Data Sheet for information regarding hazards and safe handling practices.
Storage/Stability
Store at -70 °C. Repeated freezing and thawing, or storage in "frost-free" freezers, is not recommended. If slight turbidity occurs upon prolonged storage, clarify the solution by centrifugation before use. Working dilution samples should be discarded if not used within 12 hours.

Product Profile
Immunoblotting: a working antibody dilution of 1:500-1:20,000 is recommended using mouse brain extract.

Immunohistochemistry: a working antibody dilution of 1:500-1:20,000 is recommended. In immunohistochemistry labeling, an antigen retrieval step is necessary, e.g., pretreat the sections by incubating the tissue sections at 90 °C in a 50 mM citrate buffer. Cell body labeling is optimized when Triton™ is omitted from the tissue processing. Axon terminal labeling is substantially increased (and cell body labeling decreased) when Triton is included.

Note: In order to obtain the best results in various techniques and preparations, we recommend determining the optimal working dilution by titration.

References

Triton is a trademark of The Dow Chemical Company or an affiliated company of Dow
TD,GA,PHC,SM 07/20-1